Stephens Investment Management Group LLC Sells 66,796 Shares of Halozyme Therapeutics, Inc. $HALO

Stephens Investment Management Group LLC decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,225,181 shares of the biopharmaceutical company’s stock after selling 66,796 shares during the period. Halozyme Therapeutics makes up approximately 1.2% of Stephens Investment Management Group LLC’s holdings, making the stock its 22nd largest holding. Stephens Investment Management Group LLC’s holdings in Halozyme Therapeutics were worth $89,855,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC grew its position in Halozyme Therapeutics by 2,136.0% during the third quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after acquiring an additional 22,813 shares during the last quarter. Arbor Investment Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $1,316,000. Monument Capital Management purchased a new position in Halozyme Therapeutics in the 3rd quarter worth $2,015,000. Redhawk Wealth Advisors Inc. lifted its stake in Halozyme Therapeutics by 14.8% in the second quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock worth $1,947,000 after purchasing an additional 4,827 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its position in Halozyme Therapeutics by 2,054.7% during the third quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock valued at $35,121,000 after buying an additional 456,649 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $71.21 on Friday. The business has a 50 day moving average of $68.70 and a 200 day moving average of $67.27. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $79.50. The company has a market cap of $8.37 billion, a PE ratio of 14.99, a P/E/G ratio of 0.32 and a beta of 0.94. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. During the same period in the previous year, the firm earned $1.27 EPS. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analyst Weigh In

HALO has been the topic of several analyst reports. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Leerink Partnrs raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Zacks Research lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, December 29th. Finally, Citizens Jmp upped their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.80.

Insider Buying and Selling

In other news, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $68.48, for a total value of $136,960.00. Following the completion of the transaction, the director owned 42,952 shares of the company’s stock, valued at approximately $2,941,352.96. This represents a 4.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total value of $1,382,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $50,721,994.47. The trade was a 2.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,661 shares of company stock valued at $3,139,257 over the last three months. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.